View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar II. Belgyógyászati Klinika Budapest Szentkirályi u. 46. 1088
  • 2 Magyar Tudományos Akadémia Molekuláris Medicina Kutatócsoport Budapest
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

A Helicobacter pylori -fertőzés első vonalbeli kezelését a hétnapos protonpumpagátló-alapú (PPI+clarythromycin+amoxycillin vagy metronidazol) kombinált terápia jelenti. A kezelés sikeressége a nemzetközi adatok alapján 80-90%, hazánkban 75%. Az esetek 10-25%-ában ismételt kezelés szükséges. A hazai gyakorlatban a második eradikációs kezelés 36%-ban, a harmadik csak 20%-ban sikeres. A Helicobacter pylori -ellenes kezelés sikeressége világszerte csökken, aminek a hátterében a bakteriális, főleg a clarythromycinrezisztencia gyakoribbá válása áll. Fontos tényező még a betegek nem megfelelő együttműködése és a gyógyszerhatóanyag farmakogenetikai, -kinetikai tulajdonságai. A gyakori metronidazol- és clarythromycinrezisztenciájú területeken az eredmények elfogadhatatlanul alacsonyak, új gyógyszerek, gyógyszer-kombinációk alkalmazása lenne kívánatos. Lehetséges megoldás a szekvenciális kezelés, illetve az újabb antibiotikumok (például levofloxacin) használata. Más természetes hatóanyagok alkalmazása (laktoferrin, probiotikumok, növényi kivonatok) további vizsgálatokat igényel.

  • Gastroenterologia. Szerk.: Varró V. Medicina Könyvkiadó Rt., Budapest, 1998, 105–108.

    '', in Gastroenterologia , (1998 ) -.

  • Vakil, N., Megraud, F.: Eradication therapy for Helicobacter pylori . Gastroenterology, 2007, 133 , 985–1001.

    Megraud F. , 'Eradication therapy for Helicobacter pylori ' (2007 ) 133 Gastroenterology : 985 -1001.

    • Search Google Scholar
  • Mohammadi, M., Doroud, D., Mohajerani, N. és mtsa: Helicobacter pylori antibiotic resistance in Iran. W. J. Gastroenterol., 2005, 11 , 6009–6013.

    Mohajerani N. , 'Helicobacter pylori antibiotic resistance in Iran ' (2005 ) 11 W. J. Gastroenterol. : 6009 -6013.

    • Search Google Scholar
  • Wolle, K., Malfertheiner, P.: Treatment of Helicobacter pylori . Best Pract. Res. Clin. Gastroenterol., 2007, 21 , 315–324.

    Malfertheiner P. , 'Treatment of Helicobacter pylori ' (2007 ) 21 Best Pract. Res. Clin. Gastroenterol. : 315 -324.

    • Search Google Scholar
  • Malfertheiner, P., Megraud, F., O’Morain, C. és mtsai, The European Helicobacter pylori Study Group (EHSG): Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut, 2007, 56 , 772–781.

    O’Morain C. , 'Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report ' (2007 ) 56 Gut : 772 -781.

    • Search Google Scholar
  • Vakil, N., Lanza, F., Schwartz, H. és mtsa: Seven-day therapy for Helicobacter pylori in the United States. Aliment. Pharmacol. Ther., 2004, 20 , 99–107.

    Schwartz H. , 'Seven-day therapy for Helicobacter pylori in the United States ' (2004 ) 20 Aliment. Pharmacol. Ther. : 99 -107.

    • Search Google Scholar
  • Zagari, R. M., Bianchi-Porro, G., Fiocca, R. és mtsai: Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut, 2007, 56 , 475–479.

    Fiocca R. , 'Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study ' (2007 ) 56 Gut : 475 -479.

    • Search Google Scholar
  • Prónai, L., Tulassay, Zs.: Failure of Helicobacter pylori eradication – suggestion for further therapy. Orv. Hetil., 2003, 144 , 1299–1302.

    Tulassay Zs. , 'Failure of Helicobacter pylori eradication – suggestion for further therapy ' (2003 ) 144 Orv. Hetil. : 1299 -1302.

    • Search Google Scholar
  • Katelaris, P. H., Forbes, G. M., Talley, N. J. és mtsa: A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology, 2002, 123 , 1763–1769.

    Talley N. J. , 'A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study ' (2002 ) 123 Gastroenterology : 1763 -1769.

    • Search Google Scholar
  • Rodríguez-Torres, M., Salgado-Mercado, R., Ríos-Bedoya, C. F. és mtsai: High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin. Dig. Dis. Sci., 2005, 50 , 634–639.

    Ríos-Bedoya C. F. , 'High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin ' (2005 ) 50 Dig. Dis. Sci. : 634 -639.

    • Search Google Scholar
  • Gisbert, J. P., Gisbert, J. L., Marcos, S. és mtsai: Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. Aliment. Pharmacol. Ther., 2005, 22 , 1041–1046.

    Marcos S. , 'Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin ' (2005 ) 22 Aliment. Pharmacol. Ther. : 1041 -1046.

    • Search Google Scholar
  • Furuta, T., Sugimoto, M., Shirai, N. és mtsai: Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori . Aliment. Pharmacol. Ther., 2007, 26 , 693–703.

    Shirai N. , 'Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori ' (2007 ) 26 Aliment. Pharmacol. Ther. : 693 -703.

    • Search Google Scholar
  • Zambon, C. F., Basso, D., Navaglia, F. és mtsai: Pro- and anti-inflammatory cytokines gene polymorphisms and Helicobacter pylori infection: interactions influence outcome. Cytokine, 2005, 29 , 141–152.

    Navaglia F. , 'Pro- and anti-inflammatory cytokines gene polymorphisms and Helicobacter pylori infection: interactions influence outcome ' (2005 ) 29 Cytokine : 141 -152.

    • Search Google Scholar
  • Zambon, C. F., Fasolo, M., Basso, D. és mtsai: Clarithromycin resistance, tumor necrosis factor alpha gene polymorphism and mucosal inflammation affect H. pylori eradication success. J. Gastrointest. Surg., 2007, 11 , 1506–1514.

    Basso D. , 'Clarithromycin resistance, tumor necrosis factor alpha gene polymorphism and mucosal inflammation affect H. pylori eradication success ' (2007 ) 11 J. Gastrointest. Surg. : 1506 -1514.

    • Search Google Scholar
  • Camargo, M. C., Piazuelo, M. B., Mera, R. M. és mtsai: Effect of smoking on failure of H. pylori therapy and gastric histology in a high gastric cancer risk area of Colombia. Acta Gastroenterol. Latinoam., 2007, 37 , 238–245.

    Mera R. M. , 'Effect of smoking on failure of H. pylori therapy and gastric histology in a high gastric cancer risk area of Colombia ' (2007 ) 37 Acta Gastroenterol. Latinoam. : 238 -245.

    • Search Google Scholar
  • Abdullahi, M., Annibale, B., Capoccia, D. és mtsai: The eradication of Helicobacter pylori is Affected by Body Mass Index (BMI). Obes Surg., 2008 Apr 29. [Epub ahead of print.

  • Glupczynski, Y., Mégraud, F., Lopez-Brea, M. és mtsa: European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori . Eur. J. Clin. Microbiol. Infect. Dis., 2001, 20 , 820–823.

    Lopez-Brea M. , 'European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori ' (2001 ) 20 Eur. J. Clin. Microbiol. Infect. Dis. : 820 -823.

    • Search Google Scholar
  • Duck, W. M., Sobel, J., Pruckler, J. M. és mtsai: Antimicrobial resistance incidence and risk factors among Helicobacter pylori -infected persons, United States. Emerg. Infect. Dis., 2004, 10 , 1088–1094.

    Pruckler J. M. , 'Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States ' (2004 ) 10 Emerg. Infect. Dis. : 1088 -1094.

    • Search Google Scholar
  • De Francesco, V., Margiotta, M., Zullo, A. és mtsai: Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15-year period in Italy. J. Antimicrob. Chemother., 2007, 59 , 783–785.

    Zullo A. , 'Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15-year period in Italy ' (2007 ) 59 J. Antimicrob. Chemother. : 783 -785.

    • Search Google Scholar
  • Mohammadi, M., Doroud, D., Mohajerani, N. és mtsa: Helicobacter pylori antibiotic resistance in Iran. W. J. Gastroenterol., 2005, 11 , 6009–6013.

    Mohajerani N. , 'Helicobacter pylori antibiotic resistance in Iran ' (2005 ) 11 W. J. Gastroenterol. : 6009 -6013.

    • Search Google Scholar
  • Furuta, T., Soya, Y., Sugimoto, M. és mtsai: Modified allele-specific primer-polymerase chain reaction method for analysis of susceptibility of Helicobacter pylori strains to clarithromycin. J. Gastroenterol. Hepatol., 2007, 22 , 1810–1815.

    Sugimoto M. , 'Modified allele-specific primer-polymerase chain reaction method for analysis of susceptibility of Helicobacter pylori strains to clarithromycin ' (2007 ) 22 J. Gastroenterol. Hepatol. : 1810 -1815.

    • Search Google Scholar
  • Matteo, M. J., Granados, G., Olmos, M. és mtsai: Helicobacter pylori amoxicillin heteroresistance due to point mutations in PBP-1A in isogenic isolates. J. Antimicrob. Chemother., 2008, 61 , 474–477.

    Olmos M. , 'Helicobacter pylori amoxicillin heteroresistance due to point mutations in PBP-1A in isogenic isolates ' (2008 ) 61 J. Antimicrob. Chemother. : 474 -477.

    • Search Google Scholar
  • Gerrits, M. M., Berning, M., Van Vliet, A. H. és mtsai: Effects of 16S rRNA gene mutations on tetracycline resistance in Helicobacter pylori . Antimicrob. Agents Chemother., 2003, 47 , 2984–2986.

    Vliet A. H. , 'Effects of 16S rRNA gene mutations on tetracycline resistance in Helicobacter pylori ' (2003 ) 47 Antimicrob. Agents Chemother. : 2984 -2986.

    • Search Google Scholar
  • Glocker, E., Bogdan, C., Kist, M.: Characterization of rifampicin-resistant clinical Helicobacter pylori isolates from Germany. J. Antimicrob. Chemother., 2007, 59 , 874–879.

    Kist M. , 'Characterization of rifampicin-resistant clinical Helicobacter pylori isolates from Germany ' (2007 ) 59 J. Antimicrob. Chemother. : 874 -879.

    • Search Google Scholar
  • Lee, C. C., Lee, V. W., Chan, F. K. és mtsa: Levofloxacin-resistant Helicobacter pylori in Hong Kong. Chemotherapy, 2008, 54 , 50–53.

    Chan F. K. , 'Levofloxacin-resistant Helicobacter pylori in Hong Kong ' (2008 ) 54 Chemotherapy : 50 -53.

    • Search Google Scholar
  • Han, F., Liu, S., Ho, B. és mtsai: Alterations in rdxA and frxA genes and their upstream regions in metronidazole-resistant Helicobacter pylori isolates. Res. Microbiol., 2007, 158 , 38–44.

    Ho B. , 'Alterations in rdxA and frxA genes and their upstream regions in metronidazole-resistant Helicobacter pylori isolates ' (2007 ) 158 Res. Microbiol. : 38 -44.

    • Search Google Scholar
  • Zullo, A., De Francesco, V., Hassan, C. és mtsai: The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut, 2007, 56 , 1353–1357.

    Hassan C. , 'The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis ' (2007 ) 56 Gut : 1353 -1357.

    • Search Google Scholar
  • Graham, D. Y., Lu, H., Yamaoka, Y.: Therapy for Helicobacter pylori infection can be improved. Sequential therapy and beyond. Drugs, 2008, 68 , 725–736.

    Yamaoka Y. , 'Therapy for Helicobacter pylori infection can be improved. Sequential therapy and beyond ' (2008 ) 68 Drugs : 725 -736.

    • Search Google Scholar
  • Gisbert, J. P., Pajares, R., Pajares, J. M.: Evolution of Helicobacter pylori therapy from a meta-analytical perspective. Helicobacter, 2007, 12 (Suppl. 2) , 50–58.

    Pajares J. M. , 'Evolution of Helicobacter pylori therapy from a meta-analytical perspective ' (2007 ) 12 Helicobacter : 50 -58.

    • Search Google Scholar
  • Chey, W. D., Wong, B. C; Practice Parameters Committee of the American College of Gastroenterology: American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am. J. Gastroenterol., 2007, 102 , 1808–1825.

    Wong B. C. , 'American College of Gastroenterology guideline on the management of Helicobacter pylori infection ' (2007 ) 102 Am. J. Gastroenterol. : 1808 -1825.

    • Search Google Scholar
  • Gisbert, J. P., Bermejo, F., Castro-Fernández, M. és mtsai: Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am. J. Gastroenterol., 2008, 103 , 71–76.

    Castro-Fernández M. , 'Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients ' (2008 ) 103 Am. J. Gastroenterol. : 71 -76.

    • Search Google Scholar
  • Van der Poorten, D., Katelaris, P. H.: The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice. Aliment. Pharmacol. Ther., 2007, 26 , 1537–1542.

    Katelaris P. H. , 'The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice ' (2007 ) 26 Aliment. Pharmacol. Ther. : 1537 -1542.

    • Search Google Scholar
  • Di Mario, F., Cavallaro, L. G., Scarpignato, C.: „Resue” therapies for the management of Helicobacter pylori infection. Dig. Dis., 2006, 24 , 113–130.

    Scarpignato C. , '„Resue” therapies for the management of Helicobacter pylori infection ' (2006 ) 24 Dig. Dis. : 113 -130.

    • Search Google Scholar
  • Di Mario, F., Aragona, G., Dal Bó, N. és mtsai: Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. Aliment. Pharmacol. Ther., 2006, 23 , 1235–1240.

    Dal Bó N. , 'Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study ' (2006 ) 23 Aliment. Pharmacol. Ther. : 1235 -1240.

    • Search Google Scholar
  • Yamauchi, K., Wakabayashi, H., Shin, K. és mtsa: Bovine lactoferrin: benefits and mechanism of action against infections. Biochem. Cell Biol., 2006, 84 , 291–296.

    Shin K. , 'Bovine lactoferrin: benefits and mechanism of action against infections ' (2006 ) 84 Biochem. Cell Biol. : 291 -296.

    • Search Google Scholar
  • de Bortoli, N., Leonardi, G., Ciancia, E. és mtsai: Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am. J. Gastroenterol., 2007, 102 , 951–956.

    Ciancia E. , 'Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics ' (2007 ) 102 Am. J. Gastroenterol. : 951 -956.

    • Search Google Scholar
  • Gotteland, M., Brunser, O., Cruchet, S.: Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? . Aliment. Pharmacol. Ther., 2006, 23 , 1077–1086.

    Cruchet S. , 'Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? ' (2006 ) 23 Aliment. Pharmacol. Ther. : 1077 -1086.

    • Search Google Scholar
  • Nostro, A., Cellini, L., Di Bartolomeo, S. és mtsai: Antibacterial effect of plant extracts against Helicobacter pylori . Phytother. Res., 2005, 19 , 198–202.

    Bartolomeo S. , 'Antibacterial effect of plant extracts against Helicobacter pylori ' (2005 ) 19 Phytother. Res. : 198 -202.

    • Search Google Scholar
  • Moayyedi, P.: The health economics of Helicobacter pylori infection. Best Pract. Res. Clin. Gastroenterol., 2007, 21 , 347–361.

    Moayyedi P. , 'The health economics of Helicobacter pylori infection ' (2007 ) 21 Best Pract. Res. Clin. Gastroenterol. : 347 -361.

    • Search Google Scholar